Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NW-301V and NW-301D in Advanced Solid Tumor
NCT06478251Phase 1Active, not recruiting
- Start
- Feb 2024
- Primary completion
- Jun 2025
- Modality
- Prophylactic Vaccines, Gene Editing, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of NW-301V and NW-301D in solid tumor (2 cohorts). Primary endpoint: Dose-limiting toxicity at 28 days. Started Feb 2024; status: active, not recruiting.
02
Drugs
NW-301VNW-301D
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06478251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06478251.